BioCryst Pharmaceuticals (BCRX) Posts Wider than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.94 --0%
EPS Growth %: -13.3%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
DTGI, OCCI, MAYS, More
EPS Growth %: -13.3%
Financial Fact:
Total expenses: 17M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
BioCryst Pharmaceuticals (Nasdaq: BCRX) reported Q1 loss of ($0.29), $0.09 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $17.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
- American Outdoor Brands (AOUT) Tops Q4 EPS by 14c
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
